Luc Truyen

Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership positions, primarily within neuroscience. He has a strong track record in clinical development resulting in several global innovative drug approvals.

In his most recent position, Luc was global head of development for neuroscience at JNJ and managed the strategy and delivery of the early and late portfolio of assets for mood disorders and schizophrenia, and neurodegenerative and neuroinflammatory disorders.

His broad-based experience also includes leading global clinical development operations for the whole JNJ pharmaceutical group as well as serving as Head of R&D and CMO of Janssen Alzheimer Immunotherapy (JAI), an internal spin-out from JNJ. Luc holds an M.D. and Ph.D. in Neurology from the University of Antwerp.